pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,052 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1564Endpoints1224BioSpace565Fierce Biotech562BioPharma Dive467raps192onclive165fda recalls102
therapy area
allOncology10451Rare Disease2756Immunology2462Cardiology2283Hematology1887Pulmonology1875Vaccines
  • Pennsylvania reports four measles deaths this year, CDC records only two
    Pennsylvania health officials say four people have died from measles so far in 2026. The Centers for Disease Control and Prevention, however, lists only two measles deaths in its national count. T…
    STAT · 21d agoNeutral↗ source
  • STAT releases AI Prognosis newsletter on health tech leaders' policy discussions in Washington
    STAT's AI Prognosis newsletter issued a new edition that looks at what health technology executives are saying about policy issues in Washington. The piece was authored by Brittany Trang, a Ph.D.…
    STAT · 21d agoNeutral↗ source
← prev
page 19 of 123
next →
fda medwatch93
globenewswire health73
fda press54
1646
Psychiatry & CNS1107
Ophthalmology870
Endocrinology & Metabolism689
Pain656
Nephrology645
AstraZeneca invests $2 billion in Summit Therapeutics to advance PD-1xVEGF bispecific ivonescimab with ADC combos
AstraZeneca is committing $2 billion to Summit Therapeutics, acquiring a 12% equity stake at a premium to the biotech's closing price. The funding is aimed at accelerating development of the PD‑1xV…
Fierce Biotech · 22d agoDealPositive↗ source
  • FDA approves Egetis’ Emcitate for rare genetic disease as Novo secures Chinese weight-loss pill in $2.6 billion deal
    The U.S. Food and Drug Administration has granted approval to Egetis' Emcitate, a therapy targeting a rare genetic disorder. This marks a regulatory milestone for the company and patients awaiting…
    raps · 22d agoDealPositive↗ source
  • Novo Nordisk signs $2.6 billion deal with China's Hengrui for oral GLP-1/GIP candidate
    Novo Nordisk announced a licensing agreement with Chinese drugmaker Hengrui Pharmaceuticals, paying $300 million upfront for rights to a preclinical GLP-1/GIP dual-receptor agonist. The candidate,…
    Fierce Biotech · 22d agoDealPositive↗ source
  • AstraZeneca puts $2 billion into Summit Therapeutics and partners to test ivonescimab with its oncology pipeline
    AstraZeneca announced a $2 billion equity investment in Summit Therapeutics, acquiring roughly 109,000 shares of convertible preferred stock. The deal will give AstraZeneca about a 12% stake in Sum…
    BioPharma Dive · 22d agoDealNeutral↗ source
  • UniQure’s gene therapy still slows Huntington’s disease after four years, but benefit declines
    UniQure reported that its one‑time gene therapy, AMT‑130, continues to decelerate the progression of Huntington’s disease four years after being surgically delivered into patients' brains. A new a…
    STAT · 22d agoNegative readoutNegative↗ source
  • Lawmakers ask Trump to reconsider rule that would tighten import of prescription drugs from Canada
    Congressional members are pressing the Trump administration to revisit a federal rule slated to take effect on Oct. 22 that would tighten how prescription medicines are imported from Canada and oth…
    STAT · 21d agoRegulatoryNegative↗ source
  • Beam Therapeutics sues YolTech and Serapha Bio over alleged theft of base editing trade secrets
    Beam Therapeutics has filed a lawsuit in U.S. District Court in Massachusetts accusing Chinese biotech YolTech Therapeutics and its U.S. partner Serapha Bio of using confidential information to dev…
    BioPharma Dive · 21d agoNegative↗ source
  • Novo to pay Hengrui up to $2.6 billion for rights to weekly obesity pill HRS-1596
    Novo announced a deal with China-based Hengrui Pharma, paying $300 million up front for rights to HRS-1596, a once‑weekly obesity pill. The agreement could rise to $2.6 billion if the candidate me…
    BioPharma Dive · 22d agoDealNeutral↗ source
  • Anthropic joins ARPA‑H clinical AI moonshot and will host a closed‑door health‑care event
    Anthropic, an artificial‑intelligence firm, announced it is joining a new clinical‑AI initiative launched by the U.S. Biomedical Advanced Research Projects Agency‑Health (ARPA‑H). The partnership…
    STAT · 22d agoNeutral↗ source
  • AstraZeneca commits $2 billion to partner Summit Therapeutics on bispecific cancer antibody
    AstraZeneca has announced a $2 billion investment to work with Summit Therapeutics. The deal will fund the testing of Summit’s bispecific antibody, ivonescimab, which targets both PD‑1 and VEGF pat…
    STAT · 22d agoDealPositive↗ source
  • Novo to pay up to $2.6 billion for rights to Hengrui’s experimental weekly obesity pill
    Novo Pharmaceuticals has signed a licensing agreement with China's Hengrui Pharma to acquire an experimental oral weight‑loss drug that is administered once a week. Under the deal, Novo could pay…
    STAT · 22d agoDealNeutral↗ source
  • ai3Bio raises $48 million to develop T-helper cell-targeted immune-reset therapies
    ai3Bio, a new biotech startup formed from Corner Therapeutics and Novasenta, announced it has secured $48 million in an early-stage venture capital round. The company aims to create treatments for…
    BioPharma Dive · 22d agoDealPositive↗ source
  • Highlight Therapeutics reports positive Phase 2b results for BO-112 in high‑risk head and neck basal cell carcinoma
    Highlight Therapeutics announced that its Phase 2b study of BO-112 met the primary endpoint of visual and pathological response at week 24 in patients with localized high‑risk head and neck basal c…
    Fierce Biotech · 22d agoPositive readoutPositive↗ source
  • uniQure shares tumble 41% after Huntington’s gene therapy misses primary endpoint
    uniQure reported updated 48‑month data from its phase 1/2 trial of AMT‑130 in Huntington’s disease. The therapy showed a 44% slowing of disease progression on the composite Unified Huntington’s Dis…
    Fierce Biotech · 22d agoNegative readoutNegative↗ source
  • Midterm elections could reshape drug pricing, Medicaid funding and research support, industry leaders warn
    The November midterm elections are set to influence major health-care policy debates in Washington, according to STAT+. Industry leaders say the outcome could affect Medicaid funding levels, the p…
    STAT · 22d agoRegulatoryNeutral↗ source
  • CMS ends automatic Medicare bonuses for FDA breakthrough devices
    CMS announced that beginning in October, devices carrying the FDA’s breakthrough designation will no longer receive automatic extra payments from Medicare. The change removes the special pathway th…
    STAT · 22d agoRegulatoryNegative↗ source
  • MAHA Institute pushes for broader health data sharing to aid research on chronic disease and autism
    At a recent event, the Make America Healthy Again (MAHA) Institute, linked to allies of Robert F. Kennedy Jr., argued that opening health records to federal researchers could accelerate studies of…
    STAT · 22d agoRegulatoryPositive↗ source
  • Regulators Discuss Plans to Streamline Europe’s Drug Approval Process at 2026 RAPS Convergence
    A panel of European regulators gathered at the 2026 RAPS Convergence in Charlotte, North Carolina to discuss ongoing initiatives aimed at simplifying the continent’s regulatory framework. The offi…
    raps · 22d agoRegulatoryNeutral↗ source
  • FDA releases draft guidance on requirements for robotically assisted surgical devices
    The FDA has published a draft guidance outlining its thinking on the requirements for bringing certain robotically assisted surgical devices to market. The guidance describes both non-clinical and…
    raps · 22d agoRegulatoryNeutral↗ source
  • Beam Therapeutics sues former scientist over alleged IP theft to launch Chinese biotech YolTech
    Beam Therapeutics, a Cambridge‑based gene‑editing company, has filed a lawsuit accusing a former scientist of stealing proprietary data. The complaint says Zi Jun "Emma" Wang accessed Beam's elect…
    STAT · 22d agoNegative↗ source
  • Ontario launches $5M QuickStart program to cut clinical trial start-up time to 45 days
    Ontario’s Clinical Trials Ontario has introduced a $5 million QuickStart program that promises to reduce the time needed to launch a clinical trial to as little as 45 days. The initiative is desig…
    Fierce Biotech · 22d agoRegulatoryPositive↗ source
  • Biopharma layoffs ease in Q3 2026, but cuts still ongoing
    Recruiters note that biopharma layoff volume in Q3 2026 remained modest, suggesting the sector is moving past the large wave of cuts seen last year. Fierce recorded 21 layoff announcements between…
    Fierce Biotech · 22d agoLayoffsNegative↗ source
  • MAHA Summit Shows Grassroots Health Movement Aligning with Industry Leaders
    The recent MAHA Summit brought together federal officials and health‑care executives, marking a shift from the movement’s original grassroots stance. At a panel on affordability, leaders from Unit…
    STAT · 21d agoNegative↗ source